Dual Enzyme-Responsive Zwitterionic Peptides: Advancing Cancer Selectivity via Intralysosomal Self-Assembly

Study Background and Research Question

Cancer chemotherapy remains challenged by poor selectivity—most drugs harm both cancerous and healthy cells, leading to severe side effects and limited therapeutic indices. Peptide-based therapeutics have emerged as promising alternatives due to their biocompatibility and tunable functions. Of particular interest are peptide amphiphiles that undergo enzyme-instructed self-assembly within cancer cells, disrupting cellular organelles and inducing cell death. However, maximizing selectivity and minimizing off-target toxicity remain unmet needs in the field. The study by Kim et al. (Biomacromolecules, 2026) addresses the critical question: can dual enzyme-responsiveness and zwitterionic design be combined to achieve superior cancer selectivity in peptide therapeutics?

Key Innovation from the Reference Study

The core innovation of this work is the development of a zwitterionic peptide amphiphile that is responsive to two distinct cancer-associated enzymes: matrix metalloproteinase-7 (MMP-7) and cathepsin B (CTSB). Unlike previous strategies that exploited single enzyme responsiveness or cationic peptides—which often led to nonspecific uptake and off-target toxicity—the authors introduce a dual-enzyme system. This approach leverages differential enzyme expression patterns in cancer versus normal cells, enabling a two-step, intracellularly confined peptide assembly mechanism. The incorporation of both positively and negatively charged amino acids produces an overall charge-neutral (zwitterionic) peptide, further reducing nonspecific interactions with healthy cells. This is a significant advance over prior designs, which often suffered from unwanted interactions due to net peptide charge (see also).

Methods and Experimental Design Insights

The researchers designed peptide amphiphiles that incorporate (1) a self-assembly motif, (2) enzyme-cleavable sequences sensitive to MMP-7 and CTSB, and (3) negatively charged glutamic acid residues to achieve zwitterionic balance. The assembly state of the peptide is sequentially modulated by these enzymes: MMP-7 first cleaves the peptide, allowing cell uptake, and CTSB then triggers intralysosomal self-assembly. This two-step enzymatic sequence is critical for confining self-assembly to cancer cell lysosomes. The peptide constructs were synthesized using standard solid phase peptide synthesis (SPPS) protocols, where high coupling efficiency and racemization resistance are essential. The study monitored peptide assembly and disassembly via electron microscopy and fluorescence assays, and evaluated cytotoxicity and selectivity in both in vitro (cancer and normal cell lines) and in vivo (HT-29 xenograft mouse model) settings. Lysosomal integrity was assessed using membrane permeabilization assays.

Protocol Parameters

• Peptide Design: Incorporate MMP-7 and cathepsin B-cleavable sequences, with glutamic acid residues to ensure zwitterionic charge balance.
• Solid Phase Peptide Synthesis: Employ coupling reagents with high efficiency and racemization resistance to preserve peptide integrity (see discussion below).
• In vitro evaluation: Test cytotoxicity at low micromolar concentrations across cancer and normal cell lines; calculate cancer selectivity index (ratio of IC₅₀ values).
• In vivo studies: Use human colorectal adenocarcinoma (HT-29) xenograft models; monitor tumor regression and assess systemic toxicity.

Core Findings and Why They Matter

The dual enzyme-responsive peptide amphiphile demonstrated a remarkable cancer selectivity index of 64.1, far surpassing previous peptide designs. This selectivity is achieved by restricting self-assembly and subsequent lysosomal disruption to cancer cells, which co-express MMP-7 and CTSB. In normal cells lacking these enzymes, the peptide remains inert, minimizing off-target effects. At low micromolar concentrations, the peptide induced pronounced cancer cell death via lysosomal membrane permeabilization, but was non-toxic to normal cells. In vivo, the peptide achieved significant tumor regression in HT-29 xenograft mice without observable systemic toxicity (details here). These results highlight the potential of dual enzyme-responsive, zwitterionic peptides as a highly selective, intralysosomal-acting cancer therapeutic platform.

Comparison with Existing Internal Articles

Internal resources provide valuable context for both the peptide synthesis strategy and the application of coupling reagents. For example, the article "Reliable Peptide Synthesis with HBTU" emphasizes the importance of racemization resistance and coupling efficiency in SPPS workflows—critical factors for generating high-purity, functionally specific peptides like those in this study. The mechanistic overview in "HBTU in Modern Peptide Synthesis" further underscores the need for precision and selectivity, especially when synthesizing complex, enzyme-responsive constructs. Finally, internally curated reviews of dual enzyme-responsive peptides (here) connect the present findings to broader advances in cancer-selective peptide therapeutics, highlighting the unique contribution of charge-neutral designs and sequential enzymatic activation.

Limitations and Transferability

While the reported selectivity index and in vivo efficacy are compelling, several limitations should be considered. The dependence on specific enzyme expression profiles means that the strategy may not be universally applicable across all tumor types—heterogeneity in MMP-7 and CTSB expression could impact therapeutic outcomes. The in vivo evidence is currently limited to a colorectal adenocarcinoma model; broader tumor panel validation and long-term safety studies are needed. Additionally, peptide stability and delivery in the complex human physiological environment require further optimization to ensure translational viability. Nonetheless, the mechanistic insights and the dual enzyme-responsive design offer a robust framework for next-generation, tumor-selective peptide therapeutics.

Research Support Resources

For researchers aiming to reproduce or extend these findings, the choice of peptide coupling reagent is pivotal. HBTU (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (SKU A7023) is a widely used solid phase peptide synthesis reagent, valued for its mild activation, high coupling efficiency, and resistance to racemization. These properties are essential for synthesizing complex, enzyme-responsive peptides with precise control over sequence and structure. As demonstrated in the literature, efficient carboxylic acid activation and minimization of side reactions are critical for maintaining biological activity and selectivity in advanced peptide therapeutics. Researchers can consult APExBIO for detailed handling and storage recommendations to support high-yield, high-fidelity peptide synthesis workflows.